Skip to main content
. 2022 Nov 3;14(11):2370. doi: 10.3390/pharmaceutics14112370

Table 2.

Current limitations of eukaryotic and bacterial EVs in biomedical applications.

Eukaryotic (hEVs) Bacterial (bEVs) Common Limitations
Differentiation between cell surface markers Lipopolysaccharide (LPS) toxicity Immunomodulators outburst
Inefficient purification of vesicles High inflammatory responses Low viability and inefficient growth conditions
Lack of heterogeneity High chance of infection
(pathogen-derived bEVs)
High cellular toxicity